A second large, prospective study by scientists at Fred Hutchinson Cancer Research Center that claimed to confirm the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer drew a stark industry response from supplement trade associations.
The National Community Pharmacists Association announced the introduction of a resource kit — Take Charge of Rx Benefits in Your Community — to help preempt anti-patient drug benefit designs, such as those that require the use of mail-order facilities for prescription drugs.
The Indian generic drug maker announced the approval of repaglinide tablets in the 1-mg and 2-mg strengths, which are used in combination with diet and exercise to improve blood-sugar control in patients with Type 2 diabetes.
Actavis and Warner Chilcott announced that they have each received a request for additional information from the Federal Trade Commission in connection with Actavis' pending acquisition of Warner Chilcott.
The National Advertising Division recommended that German-American Technologies modify or discontinue certain advertising claims made for the company’s Nitraflex Hyperemia & Testosterone Enhancing dietary supplement.
The Consumer Healthcare Products Association on Wednesday applauded the Pennsylvania legislature and Gov. Tom Corbett for passage of House Bill 602, legislation requiring real-time, stop-sale technology to enable retailers to block illegal pseudoephedrine purchases at the point of sale.
The National Community Pharmacists Association praised Hawaii elected officials for enacting two new laws that, respectively, will give the state’s residents greater choice of where to fill their prescriptions and additional medical privacy protections.
A nonprofit pharmacy advocacy group has launched a new project that it said was aimed at ensuring fair audit standards for prescription drug claims paid under the Medicare Part D program and protecting pharmacies and patients from what it called unfair audit and conduct practices by pharmacy benefit managers.
The Food and Drug Administration has made a significant dent in its large backlog of generic drug applications thanks to amendments to last year's reauthorization of the Prescription Drug User Fee Act, the agency said.
With some studies showing that patients' failure to take their medications as directed costs the economy nearly $300 billion per year, one group is looking to tackle what it sees as part of the problem: doctors' and pharmacists' instructions to patients on how much medicine to take and when.